HTL 0016878
Alternative Names: HTL-0016878; NBI-1117568; NBI-568Latest Information Update: 09 May 2025
At a glance
- Originator Heptares Therapeutics
- Developer AbbVie; Neurocrine Biosciences; Nxera Pharma
- Class Antidementias; Antipsychotics; Small molecules
- Mechanism of Action Muscarinic M4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Schizophrenia
- No development reported Alzheimer's disease